The thesis

Tactile Systems Technology operates in the growing medical devices sector, with 22.9% year-over-year revenue growth and a 75.68% gross margin. The company's conviction score is 25, indicating moderate confidence. Analysts have a buy consensus rating, with a DCF intrinsic value of $67. This setup is interesting given the company's strong financials and moderate conviction score.

Why now

The current macro environment, with a focus on healthcare and medical devices, makes this a compelling time to examine TCMD. The company's recent revenue growth and strong margins make it a standout in the sector, warranting attention amidst the current market dynamics.

What to watch

Investors should monitor TCMD's future revenue growth and margin expansion over the next 1-3 quarters to confirm the thesis. Key metrics to watch include the company's ability to maintain its gross margin above 75% and deliver revenue growth above 20% year-over-year.

Key risks

Valuation risk is a concern, with a P/E ratio of 32.8x, which may be elevated given the company's growth prospects. Execution risk is also a factor, as TCMD must continue to deliver strong revenue growth to justify its current valuation. Additionally, competitive risk from other medical device manufacturers poses a threat to the company's market share.

Theme exposure